rEV 131
Alternative Names: EV-131; rEV-131Latest Information Update: 09 May 2007
Price :
$50 *
At a glance
- Originator Evolutec
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Recombinant proteins
- Mechanism of Action Histamine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Allergic conjunctivitis; Allergic rhinitis; Asthma; Chronic obstructive pulmonary disease; Postoperative inflammation
Most Recent Events
- 04 Dec 2006 A phase IIb trial of rEV 131 in Allergic rhinitis did not meet its primary endpoint
- 22 Jun 2006 Phase-II clinical trials in Postoperative inflammation in USA (Ophthalmic)
- 16 Jun 2006 Phase-II clinical trials in Allergic rhinitis in Canada (Intranasal)